+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Allergic Conjunctivitis Treatment Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780683
The growth of the global allergic conjunctivitis treatment market is being driven by the increasing prevalence of the condition worldwide and the growing investment in research and development activities. The global allergic conjunctivitis treatment is likely to grow at a rate of 6.2% during the forecast period of 2023-2031.

Allergic Conjunctivitis Treatment Market: Introduction

Allergic conjunctivitis is a common eye condition caused by allergens, such as pollen, dust, and animal dander. The condition is characterized by inflammation of the conjunctiva, leading to symptoms such as redness, itching, and watery discharge. Treatment options for allergic conjunctivitis include antihistamines, mast cell stabilizers, and corticosteroids. The global allergic conjunctivitis treatment market report provides an in-depth analysis of the market and its segments.

The market is also expected to benefit from the increasing investment in research and development activities by key players in the industry. The development of novel therapies and the increasing focus on personalized medicine are likely to create new growth opportunities for the market players. Furthermore, the expanding healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to contribute to the growth of the market.

Allergic Conjunctivitis Epidemiology

Allergic conjunctivitis is a common eye condition that affects people of all ages worldwide. It is caused by an allergic reaction to an irritant or allergen, such as pollen, dust mites, pet dander, or mould.

The prevalence of allergic conjunctivitis varies based on factors such as geography, climate, and seasonal changes. According to a report by the American Academy of Ophthalmology, allergic conjunctivitis affects approximately 20% of the population. In the United States, it is estimated that about 6 million people are affected by allergic conjunctivitis each year. The condition can affect people of all ages, but it is more common in children and young adults. Studies have shown that the prevalence of allergic conjunctivitis is higher in urban areas compared to rural areas.

Additionally, people who have a history of allergies or atopic conditions such as eczema, asthma, and allergic rhinitis (hay fever) are more likely to develop allergic conjunctivitis. The risk of developing allergic conjunctivitis also increases with exposure to allergens and irritants, such as cigarette smoke, pollution, and chemicals. Early diagnosis and appropriate treatment are crucial in managing allergic conjunctivitis and preventing complications.

Allergic Conjunctivitis Treatment Market Segmentations

The market can be categorised into diagnosis method, treatment method, and therapeutic channel.

Market Breakup by Diagnosis Method

Prenatal Testing

  • Amniocentesis
  • Chorionic Villus Sampling
  • Physical Exam
  • Blood and Urine Tests
  • Genetic Testing

Market Breakup by Treatment Method

  • Medication
  • Medications
  • Physical Exams
  • Reconstructive Surgery

Market Breakup by Therapeutic Channel

  • Public
  • Private

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Allergic Conjunctivitis Treatment Market Scenario

The increasing prevalence of the disease, rising awareness, and growing investment in research and development activities are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.

North America dominates the allergic conjunctivitis treatment market, followed by Europe and Asia Pacific. The high prevalence of allergic conjunctivitis in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for allergic conjunctivitis treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

Key Players in the Global Allergic Conjunctivitis Treatment Market

The report gives an in-depth analysis of the key players involved in the allergic conjunctivitis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Sun Pharmaceutical Industries Limited
  • Novartis AG
  • Bausch & Lomb
  • AbbVie Inc
  • Ocular Therapeutic, Inc
  • Alexion Pharmaceuticals Inc
  • Santen Pharmaceutical Co., Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Alembic Pharmaceuticals Ltd
  • Grevis Pharmaceuticals Pvt. Ltd
Frequently Asked Questions about the Global Allergic Conjunctivitis Treatment Market

What is the estimated value of the Global Allergic Conjunctivitis Treatment Market?

The Global Allergic Conjunctivitis Treatment Market was estimated to be valued at $2.26 Billion in 2023.

What is the growth rate of the Global Allergic Conjunctivitis Treatment Market?

The growth rate of the Global Allergic Conjunctivitis Treatment Market is 6.2%, with an estimated value of $3.65 Billion by 2031.

What is the forecasted size of the Global Allergic Conjunctivitis Treatment Market?

The Global Allergic Conjunctivitis Treatment Market is estimated to be worth $3.65 Billion by 2031.

Who are the key companies in the Global Allergic Conjunctivitis Treatment Market?

Key companies in the Global Allergic Conjunctivitis Treatment Market include Sun Pharmaceutical Industries Limited, Novartis AG, Bausch & Lomb, AbbVie Inc., Ocular Therapeutix, Inc., Alexion Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Ltd. and Grevis Pharmaceuticals Pvt. Ltd..

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology3 Executive Summary
4 Allergic Conjunctivitis Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Allergic Conjunctivitis Treatment Market
8.1 Global Allergic Conjunctivitis Treatment Market Overview
8.2 Global Allergic Conjunctivitis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Allergic Conjunctivitis Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Allergic Conjunctivitis Treatment Market Forecast Value (2023-2031)
8.3 Global Allergic Conjunctivitis Treatment Market by Diagnosis
8.3.1 Market Overview
8.3.1.1 Allergy Skin Test
8.3.1.2 Blood Test
8.3.1.3 Others
8.4 Global Allergic Conjunctivitis Treatment Market by Drug Class
8.4.1 Market Overview
8.4.1.1 Antihistamines and Mast Cell Stabilisers
8.4.1.2 Corticosteroids
8.4.1.3 NSAIDS
8.4.1.4 Others
8.5 Global Allergic Conjunctivitis Treatment Market by Disease Type
8.5.1 Market Overview
8.5.1.1 Seasonal Allergic Conjunctivitis
8.5.1.2 Contact Conjunctivitis
8.5.1.3 Giant Papillary Conjunctivitis
8.5.1.4 Perennial Conjunctivitis
8.5.1.5 Vernal Keratoconjunctivitis
8.5.1.6 Atopic Keratoconjunctivitis
8.6 Global Allergic Conjunctivitis Treatment Market by Treatment Channel
8.6.1 Market Overview
8.6.1.1 Public
8.6.1.2 Private
8.7 Global Allergic Conjunctivitis Treatment Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Middle East and Africa
8.7.1.5 Latin America
9 North America Allergic Conjunctivitis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Allergic Conjunctivitis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Allergic Conjunctivitis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Allergic Conjunctivitis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Allergic Conjunctivitis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Allergic Conjunctivitis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Sun Pharmaceutical Industries Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Novartis AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Bausch & Lomb
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 AbbVie Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Ocular Therapeutix, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Alexion Pharmaceuticals Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Santen Pharmaceutical Co., Ltd.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Dr. Reddy’s Laboratories Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Alembic Pharmaceuticals Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Grevis Pharmaceuticals Pvt. Ltd.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
16 Global Allergic Conjunctivitis Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Companies Mentioned

  • Sun Pharmaceutical Industries Limited
  • Novartis AG
  • Bausch & Lomb
  • AbbVie Inc.
  • Ocular Therapeutix, Inc.
  • Alexion Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Grevis Pharmaceuticals Pvt. Ltd.

Methodology

Loading
LOADING...